Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt
Research Article
Effect of Adding Vildagliptin to Metformin on Antioxidant State, Inflammatory, and Atherothrombotic Markers in Newly Diagnosed Patients with Type 2 Diabetes Mellitus
Author(s): Bassant M Mahboub*, Sahar M El-Haggar, Yasser M Abdelraouf and Gamal A Elazab
Objective: This study aimed to evaluate the effect of adding vildagliptin to metformin therapy on major CV risk parameters in newly diagnosed patients with type 2 diabetes mellitus (T2DM).
Methods: Forty three eligible patients were prospectively randomized to receive combined vildagliptin/ metformin therapy or metformin alone. Anthropometric measurements, blood pressure (BP), glycated hemoglobin (HbA1c), lipid profile, plasminogen activator inhibitor-1 (PAI-1), high sensitivity C-reactive protein (hs- CRP), and total antioxidant capacity (TAC) were assessed at baseline and after 12 weeks.
Results: Forty patients completed the study (20 in each group). At baseline, no significant differences were observed between groups in all studied parameters. After 12 weeks, combined vildagliptin/metformin showed significant re.. View More»
DOI:
10.35248/2155-6156.19.10.834
